

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 861 900 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.09.1998 Bulletin 1998/36

(21) Application number: 97102837.8

(22) Date of filing: 21.02.1997

(51) Int. Cl.⁶: C12N 15/70, C07K 16/18,
C12N 5/20, C07K 14/47,
C12N 15/06, C12N 1/21,
C12N 5/10, G01N 33/577,
G01N 33/68, A61K 39/395

(84) Designated Contracting States:
GB

(83) Declaration under Rule 28(4) EPC (expert
solution)

(71) Applicant:
ERZIEHUNGSDIREKTION OF THE CANTON
ZÜRICH
CH-8090 Zürich (CH)

(72) Inventors:
• Korth, Carsten
8008 Zürich (CH)

• Stierli, Beat
8114 Dänikon (CH)
• Moser, Markus
8037 Zürich (CH)
• Streit, Peter
8006 Zürich (CH)
• Oesch, Bruno
5233 Stilli (CH)


(74) Representative:
Emmel, Thomas, Dipl.-Biol., Dr.
Schaefer & Emmel
Gehölzweg 20
22043 Hamburg (DE)

(54) Immunological detection of prions

(57) The presented invention relates to monoclonal antibodies useful in sensitive and specific immunological assays for the identification of prions in various tissues and body fluids, the production of such monoclonal antibodies by means of immunisation of

PrP^{0/0} mice by means of a new recombinant fragment of PrP and the use of the antibodies, e. g. for therapeutic and preventive treatments of humans and animals suffering from prion diseases.

Figure 1



EP 0 861 900 A1

Description

Field of the Invention

5 The present invention relates to monoclonal antibodies reacting with certain epitopes of recombinant bovine prion protein, native and denatured normal or disease-specific prion proteins in soluble or insoluble state, stable hybridoma cell lines producing these monoclonal antibodies, recombinant expression vectors for the expression of recombinant bovine prion protein, purified recombinant bovine prion protein, a test kit for the diagnosis of prion diseases, diagnostic methods for the immunological detection of prion diseases, pharmaceutical preparations for the prevention and therapy
 10 of prion diseases, a method for clearing biological material from infective prion proteins, and methods for the production of these materials.

Abbreviations and Definitions used hereinbefore and hereinafter are the following:

BSA	bovine serum albumin
15 BSE	bovine spongiform encephalopathy
CSF	cerebrospinal fluid
CJD	Creutzfeldt-Jakob disease,
ECL	enhanced chemiluminescence
EDTA	ethylenediaminetetraacetic acid
20 ELIFA	enzyme linked immunofiltration assay
ELISA	enzyme linked immunosorbent assay
Fab	fragment of antibody digested with papain
(Fab') ₂	fragment of antibody digested with pepsin
FFI	Fatal Familial Insomnia
25 GPI-anchor	glycolipid-anchor which links PrP to the outside of the cell membrane
GSS	Gerstmann-Sträussler-Scheinker disease
H(A)T-medium	hypoxanthine-(aminopterin)-thymidine medium
HEPES	hydroxyethyl-piperazineethane sulfonic acid
HPLC	high performance liquid chromatography
30 IgG	immunoglobulin G
IPTG	isopropyl- β -D-thiogalactoside
mAB	monoclonal antibody
MOPS	morpholinepropanesulfonic acid
NC	nitrocellulose membrane
35 o/n	overnight
PBS	phosphate-buffered saline
PCR	polymerase chain reaction
prion	proteinaceous infectious particle; the infectious agent of prion diseases, supposedly consisting at least of PrP ^{Sc} and maybe another yet unknown molecule
40 PrP	prion protein; refers to the common amino acid sequence rather than to a distinct conformation of the two prion protein isoforms
PrP ^{0/0} -mice	mice lacking a functional PrP gene
PrP ^C	a normal host prion protein of unknown function; apparent molecular weight 33-35 kDa, same amino acid chain, and same glycosylation at two asparagine residues as PrP ^{Sc} , is by proteinase K treatment fully digested.
45 PrP ^{Sc}	the disease-specific, abnormal isoform of PrP ^C , with the same amino acid chain, apparent molecular weight 33-35 kDa, glycosylated at two asparagine residues, is by proteinase K treatment shortened to a 27-30 kDa C-terminal fragment. Species-specific PrP ^{Sc} isoforms are termed: human PrP ^{Sc} (PrP ^{CJD}), bovine PrP ^{Sc} (PrP ^{BSE}) etc.
50 rbPrP	recombinant bovine prion protein (amino acids 25 to 242 of the bovine PrP gene) expressed in E. coli comprising the bovine PrP open reading frame except for the N-terminal signal sequence and the C-terminal GPI-anchor sequence; both ends are cleaved during cellular processing. Since rbPrP is not glycosylated it has a molecular weight of 23 kD.
RT	room temperature
55 SAF	scrapie-associated fibrils; same as rods: plaque-like multimeric PrP ^{Sc} aggregates
SDS	sodium dodecyl sulfate
TBST	Tris-buffered saline, Tween 20
TMB	tetramethylbenzidine

Prion diseases are transmissible neurodegenerative diseases of the central nervous system (for review see Prusiner, 1991). They can be transmitted, inherited or occur sporadically and are observed in animals (e.g. bovine spongiform encephalopathy [BSE] in cattle, scrapie in sheep) as well as in humans (Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, Fatal Familial Insomnia, Kurv). Prion diseases have a characteristically long incubation period and, with the onset of clinical symptoms, lead to ataxia, dementia, psychiatric disturbances and sleeplessness before inevitable death occurs. Neuropathological changes include vacuolar degeneration of brain tissue, astrogliosis and amyloid plaque formation. In the infected subjects, neither a systemic immune response, nor an obvious specific immune response like antibody production to PrP has been observed (Kasper et al., 1982; Garfin et al., 1978) however, some mild activation of immune cells in the brain was reported (Williams et al., 1995; Williams et al., 1994).

The infectious agent appears to exist in a variety of strains, which cause distinct incubation times and histopathology (Bruce et al., 1994; Hecker et al., 1992). Transmission of prion diseases is possible between species and most easily within the same species (Prusiner, 1991).

The infectious agent, the prion, is associated with a disease-specific protein, PrP^{Sc}, that is an abnormal isoform of a host protein, PrP^C (Oesch et al., 1985; Basler et al., 1986). Both, PrP^{Sc} and PrP^C, have an apparent molecular weight of 33-35 kDa on SDS-polyacrylamide gels. They have the same amino acid sequence and are glycosylated at two asparagine residues (Oesch et al., 1985). After proteinase K treatment, PrP^{Sc} is shortened to a characteristic 27-30 kDa fragment while PrP^C is fully digested (Bolton et al., 1982; Oesch et al., 1985); this led to the conclusion that the disease-specific isoform PrP^{Sc} is partially protease resistant while the normal host isoform PrP^C is not.

Studies on the synthesis and localization of the two PrP isoforms in cultured cells have shown that PrP^C is attached to the cell surface by a glycosyl phosphatidylinositol (GPI) anchor while PrP^{Sc} accumulates intracellularly within cytoplasmic vesicles (Stahl et al., 1987). Another difference between PrP^C and PrP^{Sc} is reflected in their three-dimensional structure: PrP^{Sc} has less α helical secondary structures and increased beta sheet content as compared to PrP^C (Pan et al., 1993). So far, no chemical differences between the two isoforms have been observed (Stahl et al., 1993). In summary, PrP^{Sc} and PrP^C have the same amino acid sequence but a different folding. The misfolded prion protein is associated with infectivity and neurotoxicity.

The infectious agent is inactivated by treatments which denature proteins while reagents destroying nucleic acids have no effect (Diener et al., 1982; Alper et al., 1978). In addition, no nucleic acid essential for the infectious particle has been identified to date (see Riesner et al., 1993). This has led to the hypothesis that PrP^{Sc} itself might comprise the infectious particle (Griffith, 1967; Prusiner, 1982). According to this hypothesis, replication of infectivity is achieved by the replication of the pathogenic conformation. It is supposed that infectious PrP^{Sc} molecules convert the normal host protein PrP^C to the PrP^{Sc} conformation (Cohen et al., 1994). Conversion of PrP^C to PrP^{Sc} was claimed to have been achieved *in vitro* thereby mimicking species and strain characteristics comparable to the conversion dynamics *in vivo* (Kocisko et al., 1994; Bessen et al., 1995). However, these *in vitro* converted PrP^{Sc} molecules have, to date, not shown to be infectious.

The function of the normal host protein, PrP^C, is unknown. Mice devoid of PrP^C are viable and show no obvious signs of neurological and physical impairment (Bueler et al., 1992). In addition, these mice are not susceptible to infection with prion diseases, underlining the central importance of PrP in the replication of infectivity and/or pathology of these diseases (Bueler et al., 1993; Prusiner et al., 1993). More subtle investigations of PrP knockout mice revealed impaired synaptic function (Collinge et al., 1994) and altered sleep regulation (Tobler et al., 1996). However, a molecular function of PrP^C could not be deduced from these findings.

Prion diseases have gained public interest with the appearance of BSE in the early eighties in Great Britain (Hope et al., 1988); for review see (Wells and Wilesmith, 1995). The disease is supposed to have been transmitted by feeding prion-contaminated meat and bone meal to cattle. It is thought that BSE prions originated from scrapie-diseased sheep by crossing the species barrier from sheep to cattle. BSE has caused an epidemic of considerable importance for both, public health and cattle-dependent economy. Remarkably, no diagnostic method suitable for mass screening of infected tissues of cattle has been developed to date.

Initial diagnosis of prion diseases classically relies on the appearance of clinical symptoms. A definitive diagnosis is made by the observation of neuropathological changes in the medulla oblongata. In few cases, BSE has been shown to be transmissible to other cattle, sheep, pigs and mice. Modern diagnosis additionally uses immunological detection of PrP^{Sc} in brain sections. Since PrP^{Sc} can be detected in the CNS after half of the incubation time in experimentally infected laboratory animals (Jendroska et al., 1991; Hecker et al., 1992), it may serve as an early marker of infection. Hence, specific and sensitive detection of PrP^{Sc} allows the identification of infected animals at a subclinical stage and will help to reduce possible human health risks. By autumn 1996, the BSE epidemic has killed over 160'000 cows in Great Britain alone. In the absence of a diagnostic test, only cattle with clinical symptoms were sorted out from being further processed, allowing a great number of BSE-infected cattle to enter the human food chain (Anderson et al., 1996). This led to the suspicion that the appearance of a new variant of Creutzfeldt-Jakob disease in Great Britain was caused by transmission of BSE to humans (Will et al., 1996; Collinge et al., 1996). A sensitive detection method for

bovine PrP^{Sc} would allow the identification and removal of subclinical BSE-cases from the human food chain.

Oesch et al. (1994) have used a procedure that allows to quantitate the disease-specific isoform of PrP in hamsters. The procedure is based on an ELIFA (enzyme-linked immuno-filtration assay), and is adapted to the particularities of the prion protein, especially the poor solubility of the disease-specific isoform that has made application of conventional ELISA techniques difficult. This procedure (described in detail below) allows for testing of thousands of samples and is thus appropriate for routine screening of animals and humans for prion diseases.

Tagliavini et al. (WO 93/23432) describe a method for detecting soluble prion polypeptides. The drawback of this method is that the inventors claim to detect prion polypeptides that are soluble *in vivo*, however, it is known in the art that the disease-associated prion protein PrP^{Sc} is insoluble *in vivo*. State of the art is that insoluble PrP^{Sc} has to be solubilized *in vitro* to be detected by immunological methods. Tagliavini et al. state (page 3, line 31) "such truncated scrapie proteins have not been found to exist *in vivo* in substantially soluble form". Furthermore, the inventors give an example wherein they show soluble prion polypeptide fragments in the cerebrospinal fluid (CSF) of patients that do not suffer of the human prion disease CJD but of other unrelated diseases. However, the inventors do not show *in vivo* soluble protease-resistant prion polypeptides which would prove their hypothesis about the existence of disease-specific prion polypeptides in CSF. In addition, to show prion polypeptides in CSF they use an immunoblot (Western blot); this technique is not appropriate to detect naturally occurring soluble prion polypeptides, since the immunoblot technique requires solubilization of proteins *in vitro* prior to gel electrophoresis. This procedure would then solubilize even insoluble prion polypeptides that would be suspended in CSF.

Major shortcomings for the immunological detection of PrP have been the unavailability of excellent antibodies able to detect the native disease-specific prion protein (Kascsak et al., 1987; Barry and Prusiner, 1986; Takahashi et al., 1986; Barry et al., 1986). In particular, native PrP^{Sc} was invisible to antibodies (Serban et al., 1990). Furthermore, no monoclonal antibodies recognizing the bovine PrP were available. The reason for the difficulties in raising monoclonal as well as polyclonal antibodies is the highly conserved amino acid sequence of PrP in mammals which apparently prevents an antibody response against most epitopes.

Wisniewski et al. (US 4806627; Kascsak et al., 1987) describe the monoclonal antibody 265K3F4 produced by hybridoma cell line ATCC HB 9222 directed against scrapie-associated fibril proteins. The drawback of this method is that by immunizing wild-type mice with PrP, due to self-tolerance, an antigenic reaction against many epitopes is suppressed. Wisniewski et al. immunized wild-type mice with purified scrapie-associated fibrils (SAF) which are multimeric complexes consisting of PrP^{Sc} purified by ultracentrifugation. The obtained antibody, termed 3F4, binds only to hamster and human PrP. Furtheron, the antigen has to be denatured either by formic acid or SDS to be detected. It is stated (Kascsak et al., 1987) that the 3F4 antibody binds to undenatured SAF 10-fold weaker than to formic acid-denatured SAF. However, the fact that they fail to show the data neither in their patent application nor in their paper suggests that the 3F4 antibody does not sufficiently detect undenatured SAF. This is in accordance with our findings: repeatedly, with the 3F4 antibody it was impossible to detect undenatured SAF of protease-digested brain homogenates from hamsters (Korth & Oesch, unpublished results).

Williamson et al. (1996) have tried to circumvent the lack of an immune response to a highly conserved protein by immunizing transgenic mice lacking PrP (PrP^{0/0}-mice) with PrP, however, without success. These authors state that after immunizing PrP^{0/0}-mice with PrP "... killing these mice for hybridoma production has repeatedly yielded hybridoma cells that failed to secrete anti-PrP antibodies beyond a period of 48h". They presume that during the 48 hours after the fusion anti-PrP antibody-secreting clones either are suppressed to secrete further antibodies or die because of an interaction of the secreted antibodies with cell resident PrP. Williamson et al. tried to circumvent this problem by isolating antibody-coding RNA and constructing recombinant antibodies by the phage display technique. They obtained several recombinant antibodies which bind to non-denatured mouse prion rods (PrP^{Sc}) in the ELISA technique, however, much weaker than to denatured rods and only if substantial amounts of rods were bound to the wells (0.2 µg/well incubated with 5 µg/ml antibody). However, these recombinant antibodies do not detect native PrP^{Sc} in non-denatured histoblots. Thus, the necessity of purifying PrP^{Sc} before antibody detection complicates the use of their immunological detection method.

Krasemann et al. (1996) have produced monoclonal antibodies by means of immunizing PrP^{0/0}-mice. After DNA-immunization by injecting the DNA coding for the human prion protein directly into a regenerating muscle, the mice were subsequently boosted with Semliki Forest Virus particles comprising recombinant human prion protein. The authors present hybridoma cell lines producing monoclonal antibodies that bind to the native and denatured normal human prion protein. The binding of these antibodies to the native or denatured disease-specific prion protein, however, is not demonstrated. Furtheron, the obtained antibodies bind to a peptide ELISA system, however an ELISA to normal or disease-specific prion protein is not shown.

We are now the first to show that immunization of PrP knockout mice with highly purified recombinant PrP followed by fusion of splenocytes from these mice with myeloma cells resulted in hybridoma cell lines that secrete highly specific antibodies to both PrP isoforms (PrP^C and PrP^{Sc}) in their native as well as denatured state. On the basis of these antibodies, highly specific immunological testing for prion disease was developed.

Object of the Invention

It is an object of the present invention to overcome the drawbacks and failures of prior art and to provide monoclonal antibodies from stable hybridoma cell lines which can be used in the diagnosis and therapy of prion diseases.

Summary of the invention

Surprisingly the drawbacks of prior art can be overcome by immunization of PrP^{0/0} knockout mice with highly purified recombinant PrP followed by fusion of splenocytes from the treated mice with myeloma cells. The resulting hybridoma cell lines are surprisingly stable and secrete highly specific antibodies to both PrP isoforms (PrP^C and PrP^{Sc}) in their native as well as denatured state. The obtained antibodies are very useful for the development of highly specific immunological tests for prion diseases and other purposes.

The present invention concerns a monoclonal antibody or a fragment thereof capable of specifically binding to recombinant bovine prion protein, and native and denatured normal PrP^C and disease-specific PrP^{Sc} in an antigen-antibody complex.

The present invention concerns further an antibody or a fragment thereof capable of specifically binding to the binding region (idiotype) of said antibody.

The present invention concerns further a hybridoma cell line capable of producing a monoclonal antibody capable of specifically binding to recombinant bovine prion protein, and native and denatured normal PrP^C and disease-specific PrP^{Sc} in an antigen-antibody complex.

The present invention concerns further a recombinant expression vector for the expression of recombinant bovine prion protein.

The present invention concerns further a substantially purified recombinant bovine prion protein, which may be in reduced or oxidized form.

The present invention concerns further a method for the production of an antibody as mentioned above, comprising culturing a hybridoma cell line as mentioned above and isolating the monoclonal antibody from the supernatant.

The present invention concerns further a method for the production of a hybridoma cell line as mentioned above, comprising administering to PrP^{0/0} mice (knockout mice without a functional PrP gene) an immunizing amount of recombinant prion protein as mentioned above, removing the spleen from the immunized mice, recovering splenocytes therefrom, fusing the latter with P3X63Ag8U.1 myeloma cells (ATCC CRL 1597), growing the cells in a selection medium, screening the cells with recombinant PrP and isolating the positive cells.

The present invention concerns further a method for the production of an expression vector as mentioned above, comprising amplifying DNA from bovine genomic DNA coding for PrP by means of N- and C-terminal primers, and inserting the amplified DNA coding for PrP in the correct reading frame into an expression vector.

The present invention concerns further a method for the production of recombinant bovine prion protein comprising culturing microorganisms or cell lines with an expression vector as mentioned above in an appropriate culture medium and isolating and purifying the recombinant protein.

The present invention concerns further a test kit for the diagnosis of prion diseases.

The present invention concerns further an immunological detection procedure for the diagnosis of infective disease specific prions.

The present invention concerns further a pharmaceutical preparation for the therapy and prevention of prion diseases comprising a monoclonal antibody as mentioned above and pharmaceutical carrier.

The present invention concerns further a method for the therapy or prevention of prion diseases comprising administering to a patient suffering from such disease or being likely to becoming a victim of this disease a therapeutical or preventive amount of a monoclonal antibody as mentioned above.

The present invention concerns further a method for clearing biological material from infective prion proteins comprising treating said material with a monoclonal antibody as mentioned above.

Brief Description of the Drawings

Figure 1. a. Western blot of bovine PrP^C/PrP^{Sc} without (0µg) and after treatment with 20, 40, 80 or 100µg/ml of proteinase K for 1 hour at 37°C. The blot shows that bovine PrP^{Sc} in homogenates from thalamus (left) and spinal cord (right) of BSE-diseased and normal cattle is protease-resistant at several concentrations as compared to bovine PrP^C. Staining with mAB 6H4.

b. Western blot of different tissue homogenates from normal cattle. PrP in white blood cells is recognized by mAB 34C9.

Figure 2. Western blots of brain homogenates from different species.

a: mAB 6H4 stains PrP of all depicted species,

b: mAB 34C9 does not stain PrP from hamster and sheep; mouse PrP staining is weak. This differential staining is consistent with the sequence homology of the mapped epitopes of PrP from different species.

Figure 3. a. ELIFA standard curve. The standard curve shows a linear relation between the concentration of recombinant bovine PrP and the OD₄₅₀ with a background below 0.5 ng/ml rbPrP.

b. Results ELIFA. Both, the brain homogenates from normal and BSE-diseased cattle have high total amount of PrP as measured by the OD₄₅₀. However, while in BSE-brain there is a substantial amount of protease K-resistant PrP^{Sc}, no such PrP can be detected in normal brain.

c. Results ELISA. Both, the brain homogenates from normal and BSE-diseased cattle have high total amount of PrP as measured by the OD₄₅₀. However, while in BSE-brain there is a substantial amount of protease K-resistant PrP^{Sc}, no such PrP can be detected in normal brain.

empty column: without proteinase K treatment

black column: after proteinase treatment

Figure 4. Scheme capture ELISA and multimeric PrP^{Sc}. See also text.

a: monomeric PrP^C has no additional binding sites since the only binding site is occupied by the coating antibody.

b: multimeric disease-specific PrP^{Sc} has additional binding sites for the detecting, peroxidase-labeled mAB 6H4 (POD).

Figure 5. Schematic map of plasmid pbPrP3. The insert PrP ORF corresponds to SEQ ID NO. 1 with the restriction sites Nde I and BamH I.

Figure 6. a. Western blots of normal bovine brain homogenates and recombinant bovine

PrP. mABs 6H4 and 34C9 recognize both bovine PrP and rbPrP, whereas mAB 15B3 recognizes only rbPrP. Recombinant rbPrP runs lower and sharper than PrP from brain homogenates because it is not glycosylated.

b. Conformation-sensitive ELIFA of brain homogenates from BSE-diseased and normal cattle at different denaturation states. Staining with monoclonal antibody 15B3. While in the native state mAB 15B3 stains only bovine PrP^{Sc}, and not PrP^C, upon denaturation it stains both PrP isoforms. Denaturation in 0, 4, and 8 M urea.

Figure 7. Epitope mapping on the peptide library for bovine PrP:

a: mAB 34C9 recognizes peptides Nos. 59 to 63 of the peptide library comprising the epitopes of amino acids 149 to 153 of bovine PrP.

b: mAB 6H4 recognizes peptides Nos. 64 to 66 of the peptide library comprising the epitopes of amino acids 155 to 163 of bovine PrP.

c: mAB 15B3 recognizes peptides Nos. 73 to 79 of the peptide library comprising the epitopes of amino acids 175 to 187 of bovine PrP, and additionally Nos. 33 to 34, 53, and 69 comprising amino acid epitopes situated spatially in proximity of the epitopes of amino acids 175 to 187 of the three-dimensional bovine PrP.

Sequence Identification Listing

SEQ ID NO 1 shows the 660 base pair sequence encoding the bovine rPrP obtained from genomic bovine DNA by PCR amplification.

SEQ ID NO 2 shows the amino acid sequence of bovine rPrP which comprises amino acids 25 to 242 of the bovine PrP open reading frame except for the N terminal signal sequence and the C-terminal GPI-anchor sequence.

SEQ ID NO 3 shows the N-terminal sense primer, and

SEQ ID NO 4 shows the C-terminal antisense primer. These primers comprise a Nde I restriction site at the 5'-end and a BamH I restriction site at the 3'-end in the PCR-amplified bovine PrP-DNA.

Detailed Description of the Invention

In the following detailed description the spirit and scope of the invention will become more clearly explained and understood.

The monoclonal antibodies

A monoclonal antibody according to the invention is intended to bind to, detect and qualitatively and quantitatively measure the presence of epitopes of prion proteins, whether they are in soluble or insoluble form in various tissue specimens, such as homogenates or sections of brain, spleen, tonsils, white blood cells, or others, and body fluids, such as blood, cerebrospinal fluid saliva, urine, or others. The present mABs bind to epitopes of amino acids in a row or to epitopes of amino acids on different loops of the three-dimensional structure of native PrPs which are spatially close to each other. A particular group of the present antibodies binds only to native disease-specific PrP and not to native

normal PrP.

Any known mABs which would fall under these definitions are exempted and disclaimed.

The term monoclonal antibody comprises also chimeric monoclonal antibodies having similar properties, which are derived from different animals, such as human/mouse chimeric antibodies or any other chimeric molecule comprising the antigen-binding part of the monoclonal antibody (idiotype) with other molecules such as antibody fragments of other monoclonal antibodies or enzymes.

A fragment of a monoclonal antibody comprising the binding part of the monoclonal antibody (idiotype) is likewise capable of specifically binding the antigen and is termed Fab or (Fab')₂, depending on whether the monoclonal antibody is digested with papain or pepsin, respectively.

A synthetic antibody or fragments thereof is designed according to the amino acids or substituted homologous amino acids composing the idiotype responsible for binding the antigen. Homologous amino acids are defined as exchanges within the following five groups: 1. Small aliphatic, nonpolar or slightly polar residues: alanine, serine, threonine, glycine, proline; 2. Polar, negatively charged residues and their amides: aspartic acid, asparagine, glutamic acid, glutamine; 3. Polar, positively charged residues: histidine, arginine, lysine; 4. Large aliphatic, nonpolar residues: methionine, leucine, isoleucine, valine, cysteine; 5. Large aromatic residues: phenylalanine, tyrosine, tryptophan.

Preferred monoclonal antibodies are those named 6H4, 34C9, and 15B3 which are produced by hybridoma cell lines DSM ACC2295, DSM ACC2296 and DSM ACC2298, respectively.

The antibodies and fragments thereof are essential tools for immunological detection procedures based on the binding of the prion protein to the presented monoclonal antibodies in an antigen-antibody complex. The monoclonal antibodies of the invention react with recombinant bovine PrP as well as native or denatured PrP^C and PrP^{Sc} whether they are in soluble or insoluble state. The monoclonal antibodies react furtheron with PrP from different species, for example humans, hamsters, pigs, sheep, cattle and mice.

Furthermore, the present antibodies by forming an antigen-antibody complex between the presented monoclonal antibodies and the prior protein can be used to inhibit neurotoxic and infectious properties of the disease-specific prior protein.

Anti-idiotype antibodies

The invention concerns further anti-idiotype antibodies which are antibodies that bind with the binding region (idiotype) to the binding region of the original monoclonal antibody. The anti-idiotype antibody mimicks features of the original antigen, in this case features of PrP. Anti-idiotype antibodies are raised as polyclonal antibodies (serum) or monoclonal antibodies from animals immunized with the preferred antibodies according to the invention. Anti-idiotype antibodies are valuable tools in detecting and blocking interactions of the original antigen (PrP), particularly interactions with receptors, and can therefore be used in prevention and therapy of prion diseases.

The hybridoma cell lines

A stable hybridoma cell line according to the invention is capable of producing a monoclonal antibody as defined above over a prolonged time period of at least 6 months. Such cell lines are derived from the fusion of a spleen cell expressing the antibody derived from mice lacking a functional PrP gene, and a myeloma cell of mice providing survival of the fused cell line.

Preferred hybridoma cell lines are DSM ACC2295, DSM ACC2296 and DSM ACC2298. The first two cell lines were deposited under the Budapest Treaty on February 06, 1997, at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, a recognized public depository for strains of microorganisms. The hybridoma cell line producing mAB 15B3 was deposited February 13, 1997 unter number DSM ACC2298 at the same depository.

The expression vector for recombinant bovine prior protein

An expression vector for the expression of the recombinant bovine prior protein is a DNA vector, e. g. based on the pET11a vector by Novagen, comprising essential sequences for expression in the respective host, e. g. a promoter, such as the T7-promotor, and the DNA coding for the bovine prior protein from codons 25 to 242 with an additional codon ATG at the 5'-end of the PrP-coding DNA, and sequence for selecting, eg. the ampicillin gene, multiplication, and termination.

A preferred expression vector is pbPrP3 as shown in Figure 5.

The recombinant bovine prion protein

The present recombinant bovine prion protein comprises the amino acid sequence ID No: 2. It may be unglycosylated or glycosylated.

The present recombinant bovine prion protein Pr P is purified to a homogeneity of >98%. It can be present in oxidized or reduced form. In the oxidized form the single -S-S-bridge is present whereas in the reduced form two SH groups are present instead. The amino acid sequence of the present bovine PrP is shown by ID NO: 2. The protein is glycosylated if expressed in a glycosylating eukaryotic cell line, such as Chinese Hamster cells, or unglycosylated if expressed in a procaryotic cell line, such as *Escherichia coli*. Mixtures of the oxidized and reduced form are also comprised. The oxidized form has the molecular weight of 23676.8 D, and the reduced form 236886.1 D as determined by electrospray mass spectroscopy. The present full length recombinant bovine prion protein is unique in terms of its homogeneity, since other groups in the art have reported of being unable to purify homogenous full length recombinant prion protein of other species (Mehlhorn et al., 1996; Riek et al., 1996).

The reduced form of the recombinant PrP is particularly interesting since it has been reported to contain more β -sheet secondary structures than the oxidized form (Mehlhorn et al., 1996), hence mimicking structural features of PrP^{Sc}. However, the reduced recombinant isoforms have been reported to be neither protease-resistant nor infectious (Mehlhorn et al., 1996).

A native prion protein PrP is the prion protein polypeptide in a fully folded state, i.e. the three-dimensional structure is present. Only in the native, i.e. folded state, PrP exists in different isoforms (normal native vs. disease-specific native PrP).

A denatured prion protein is the prion protein polypeptide in the unfolded state. Unfolding is usually achieved by the addition of chaotropic substances such as urea or guanidinium hydrochloride. In the denatured state, both PrP isoforms are irreversibly the same, even if they have been normal native or disease-specific native before.

An antigen-antibody complex is a physical attachment of an antibody or fragment thereof with the corresponding antigen by intermolecular forces because the surfaces match in a unique way. The matching surface on the antibody is called idiotype and the surface on the antigen is called epitope.

Suitable epitopes detectable by the present antibodies are for example linear amino acid sequences comprising about 3 to about 15 amino acids in a row or are completely three-dimensional ("patch") in that very remote amino acid residues of the linear peptide backbone of the protein are, due to the unique folding, very close together in space to form an epitope.

The method for the production of an antibody

The present method for the production of an antibody according to the invention comprises culturing a hybridoma cell line as mentioned above and isolating the monoclonal antibody from the supernatant of the growth media.

Culturing is carried out in flasks in HT- medium or in a cell culturing system called "technomouse" in serum-free, synthetic medium (Turbodoma medium, supplied by Messi, Zurich). In a "technomouse" hybridoma cells are cultured in a sterile chamber surrounded by a protein-impermeable membrane that is perfused by the respective medium in a constant flow rate (for example, turbomedium at 80 ml/h); antibodies are collected from the chamber with the help of a syringe at regular intervals.

Isolation of monoclonal antibodies is carried out by extraction from the supernatant by conventional biochemical methods, e.g. by use of affinity columns with the corresponding immobilized antigen or by any other method used in the art, such as gel filtration or ion exchange chromatography. In the "technomouse" supplied with serum-free turbomedium antibody concentrations and purities are achieved that need no further extracting procedures.

Chimeric antibodies and fragments thereof can be produced by genetic engineering methods, e. g. by sequencing the antibody or the desired fragment thereof and constructing DNAs coding for the chimeric antibody or the fragment thereof which DNAs are inserted into an appropriate expression vector and expressed to produce the antibody or the fragment thereof in a procaryotic or eukaryotic cell line.

A fragment binding to a PrP epitope can be combined with a human heavy chain to produce chimeric antibodies for use in humans as therapeutic or preventive agents against a prion disease. A fragment binding to a PrP epitope can also be combined with other enzymes, proteins or molecules to give rise to chimeric molecules combining the biological functions of these, for example for targeting an enzymatic activity to a place defined by the proximity of the PrP epitope.

The method for the production of a hybridoma cell line

The present method for the production of a hybridoma cell line comprises administering to PrP^{0/0} mice (knockout mice without a functional PrP gene) an immunizing amount of a recombinant pure prion protein, removing the spleen from the immunized mice, recovering splenocytes therefrom, fusing the latter with appropriate myeloma cells, growing

the cells in a selection medium which does not support survival of the unfused cells, e. g. in HAT medium, screening the supernatants of the surviving hybridoma cells with recombinant PrP for the presence of antibodies to detect recombinant bovine PrP by an ELISA procedure and to detect native bovine PrP^{Sc} by a conformation-sensitive ELIFA procedure and isolating the positive cells. Positive hybridomas were selected and cloned twice by the limiting dilution method before the antibody was characterized and the epitope was mapped on a peptide library.

The peptide library used is commercially available from Jerini Biotools (Berlin, Germany). It consists of 104 spots with peptides of 13 amino acids, whereby the sequence of each peptide overlaps by 11 amino acids with the foregoing peptide.

An immunizing amount of a recombinant bovine prion protein is from about 50 to 100 µg. It is administered dissolved in an appropriate solvent, e. g. PBS and Freund's adjuvant several times, e. g. three times subcutaneously followed by an intraperitoneal and an intravenous injection shortly prior to spleen removal.

The PrP^{0/0} mice were a gift from Prof. Weissmann of the University of Zürich. They were obtained according to Büeler et al. (1992).

Appropriate myeloma cells are for example P3X63Ag8U.1, deposited and available under ATCC CRL 1597.

Recovering spleen cells and fusion conditions follow standard procedures, for example as described by Kennett (1980).

The method for the production of an expression vector

The method for the production of an expression vector comprises inserting a DNA coding for PrP in the correct reading frame into an expression vector. One of the structures of the DNA coding for PrP is shown by SEQ ID NO:1. This DNA can be obtained by amplifying DNA from bovine genomic DNA coding for PrP by means of the N- and C-terminal primers shown by SEQ ID NO: 3 and SEQ ID NO:4, respectively. Bovine genomic DNA is isolated from bovine kidney cells and supplied by Clontech, U.S.A. Degenerate allelic forms of this DNA coding for the same PrP may be used. Furthermore, targeted mutations can be introduced into the PrP DNA to give rise to distinct conformational isoforms of the translated gene product.

The production of purified recombinant bovine PrP

The production of purified recombinant bovine PrP comprises culturing a cell line with an expression vector capable of expressing the bovine PrP in an appropriate culture medium, such as in the case of *E. coli* in Luria broth medium, isolating the prion protein from the inclusion bodies by lysing the cells e. g. with lysozym and Triton-X-100 in the case of *E. coli*, solubilizing the inclusion bodies with urea and purifying the protein by conventional methods, e. g. by chromatography, for example on an anionic exchange sepharose column and a C4-reverse phase HPLC column.

The oxidized form is obtained by treatment with an oxidizing agent, e. g. with Cu₂SO₄, and the reduced form by treatment with a reducing agent, e. g. β-mercaptoethanol, according to conventional methods. They can be separated by reverse-phase high pressure liquid chromatography.

Immunological detection procedure for the detection of prion disease

An immunological detection procedure for the detection of prion disease, especially BSE, whereby disease-specific PrP^{Sc} protein in biological material of an animal or human is detected, comprises treatment of a first probe of said material with a monoclonal antibody according to the invention and detecting the mixed PrP^C/PrP^{Sc}- antibody complex, treating a second probe of said material first with proteinase K and then with the monoclonal antibody according to the invention, detecting the PrP^{Sc}-antibody complex and analyzing the results of both probes.

A specific monoclonal antibody according to the invention is able to detect PrP^{Sc} in a PrP^{Sc}-antibody complex without prior protease-digestion of the tissue specimen to be examined.

The biological material can be insoluble or soluble in buffer or body fluids. It can be derived from any part of the body, e. g. from the brain or tissue sections, in which case it is used in form of a homogenate, or any body fluid, e. g. cerebrospinal fluid, urine, saliva or blood. In the case of body fluids, fluid-resident cells, e.g. white blood cells in the case of blood expressing PrP, can be purified and analyzed either in immunohistochemistry or as a homogenate.

The detection of the PrP^{Sc}-antibody complex is carried out in particular by immunological procedures, such as Western blotting, ELIFA, and various ELISA techniques, such as capture ELISA.

The present immunological detection procedures allow the diagnosis of prion diseases. With the tools of the present invention, tissue sections, tissue homogenates or body fluids of prion-infected animals, such as BSE-diseased cattle or humans having the CJD, can be screened for the presence of the protease-resistant, disease-specific isoform of the prion protein in its native form, be it soluble or insoluble.

Tissue homogenates and body fluids are for example such as from biopsy of brain, lymph nodes, spleens, tonsils,

peripheral nerves, cerebrospinal fluids, urine, platelets or white blood cells. Particular immunological procedures comprise for example enzyme-linked immunofiltration assay (ELIFA), enzyme-linked immunoabsorbent assay (ELISA), Western blot assay, dot blot assay, immunodecoration and immunohistochemistry.

When native bovine PrP^{Sc} or any other disease-specific prion protein (e.g. ovine PrP^{Sc} or human PrP^{Sc}) has to be analyzed in immunological assays, this can presently only successfully be achieved with the antibodies described in the present invention, since the present antibodies are the first of their art to be able to bind native, disease-specific PrP^{Sc}.

The test kit for the diagnosis of prion diseases

The test kit for the diagnosis of prion diseases comprises devices and materials enabling the diagnosis of prion disease in biological materials, and is particularly suited for screening large amounts of samples for the presence of PrP^{Sc}. A test kit comprises in particular one or more monoclonal antibodies according to the invention, purified bovine recombinant PrP protein as mentioned above, nitrocellulose sheets, microtiter plates, or microtiter plates coated with the monoclonal antibodies according to the invention, a secondary anti-mouse antibody that is coupled with an enzyme and its substrate or any other molecular compound for a detection reaction (e.g. a peroxidase-labeled anti-mouse IgG antibody, TMB or any other peroxidase substrate), hydrogen peroxide, proteinase K, a blocking buffer, a homogenization buffer, a calibration curve and a description of how to perform the test.

Another test kit is designed in the dipstick format and is without need of radioactive tracers, enzymes or substrates and basically reduces the number of handling steps to one. The one-step procedure involves the capture of the disease-specific PrP^{Sc} with one of the antibodies according to the invention which are immobilized on a test strip. Captured disease-specific PrP^{Sc} is detected directly by a second antibody according to the invention, which is coupled to particular colloid particles. This specific detector complex results in the formation of coloured spots on the test strip which are visible in less than 30 minutes depending on the concentration of the test sample. The spots are a permanent record of the test result and, upon longer exposure even increase the sensitivity of the test without generating higher background.

Pharmaceutical preparation for the therapy and prevention of prion diseases

The pharmaceutical preparation for the therapy and prevention of prion diseases in a mammal, including humans, comprises an effective amount of one or more antibodies fragments thereof or chimeric antibodies as described, produced according to the invention, eventually purified according to conventional methods, and a conventional pharmaceutical carrier. An antibody obtained may be solubilized together with the carrier in an appropriate buffer, e. g. an aqueous physiological sodium chloride solution. This may be clarified by centrifugation and used in concentrated liquid form for injection, or completely dried if desired by any of the conventional methods, such as lyophilization, spray or freeze drying, in form of a dry powder, which can be pressed into tablets, filled into capsules, or applied as a dry powder in form of a nasal spray, whereby conventional production methods are applied, and conventional pharmaceutical carriers are optionally added.

Method of protecting a mammal against prion disease

The monoclonal antibodies of the present invention bind to between species highly conserved regions in the PrP molecule that may have functional significance (Oesch et al., 1991). It is envisioned that blocking this binding site by the monoclonal antibodies, fragments thereof or chimeric antibodies as defined above will abolish biological effects of prions. Blocking of the infectivity of prions by occupying distinct sites on the disease-specific form of PrP is foreseen to represent a therapeutic strategy in treating prion diseases or a preventive strategy in preincubating suspected prion-infected tissue specimens with the present monoclonal antibodies. The normal form of PrP appears not to be of vital importance in the living animal because mice with a deleted PrP gene are viable (Bueler et al., 1992). Anti-PrP antibodies may therefore be used without side effects to neutralize prions in humans or animals.

The present invention concerns further a method for the therapy or prevention of prion disease, such as a disease mediated by the neurotoxic effects of prion proteins or fragments of prion proteins, comprising administering to a patient suffering from such disease or being likely to becoming a victim of this disease a therapeutical or preventive amount of a monoclonal antibody, a fragment thereof or a chimeric antibody as described above.

The method of protecting a mammal, including a human, against an infectious prion disease according to the present invention comprises administering one or a combination of the present antibodies, fragments thereof or chimeric antibodies or a pharmaceutical preparation comprising the antibodies produced by the present invention. The pharmaceutical preparation is preferably administered by injection, e. g. intrathecally (into the cerebrospinal fluid), into the blood with respective pharmaceutical agents or methods increasing the permeability of the blood-brain barrier or as a chimeric antibody, fused to, or containing additional signal sequences that allow passage through the blood-brain bar-

rier (for review see Friden, 1994). An intranasal application of the monoclonal antibodies, fragments or chimeras thereof is also possible.

The pharmaceutical preparations have to be administered according to the judgment of the physician in amounts depending on the concentration of the antibodies comprised thereby and the route of administration so that a protective or curative effect is obtained. The amounts and method of administration are to be selected further depending upon the age and weight of the patient, the nature and severity of the infection as well as the general condition of the patient. In general it is sufficient to administer the antibodies in amounts of about 1 to 100 mg per patient in a single or in repeated doses.

Method for clearing biological material from prions

The method for clearing biological material from prions, e. g. intended for transplantation, substitution of biological material or oral consumption, comprises treating said material with one or several monoclonal antibodies according to the invention such that prions or prion proteins or fragments thereof become functionally inactivated in terms of their infectivity and/or neurotoxicity. The pharmaceutical preparations described above may be used for this purpose, whereby the pharmaceutical carrier may be replaced by a suitable other solvent in case the biological material is not intended to be used for transplantation.

The following examples serve to illustrate particular embodiments of the invention but they should not be considered a limitation thereof. The immunological procedures outlined are made for the diagnosis of BSE in cattle, however, these procedures can also be applied for prion diseases in humans or animals such as sheep, pigs, hamsters or mice.

Example 1. Immunological diagnosis of prion diseases using tissue from infected animals

PrP^C and PrP^{Sc} can be distinguished according to their different sensitivity to digestion with protease K. Undigested PrP^C and PrP^{Sc} have a molecular weight of 33-35 kDa. Upon incubation with proteinase K PrP^C is readily fully digested while PrP^{Sc} is partially resistant, i.e. the N-terminus of PrP^{Sc} is removed leading to a shift in molecular weight from 33-35 kDa to 27-30 kD (Oesch et al., 1985). Proteinase K is therefore used to digest the tissue specimen to be examined. However, monoclonal antibody 15B3, detecting a conformational epitope specific for the disease-specific isoform PrP^{Sc} may even be used without prior protease digestion.

Example 1.1. Method for the preparation of tissue homogenates

One gram of brain, either from the thalamus, medulla or spinal cord, were homogenized with an homogenizer (Omni, USA) in 10 ml 10% sucrose, 20 mM HEPES pH 7.5, 2% sarcosyl and 5 mM EDTA. 10% homogenates were diluted 10 fold; one part of the homogenate was digested with proteinase K at 0, 10 or 100 µg/ml. The probe containing 0 mg/ml served as a control for the specificity of the proteinase K treatment. Probes were then further diluted (in PBS) for the ELISA test to give a blotting concentration of 0.05% of brain homogenate. To increase the partial protease resistance of bovine PrP^{Sc}, brain homogenates from BSE-infected and normal cattle were diluted tenfold in the presence of 40 or 80% ethanol /HEPES-sucrose buffer. Suspension of brain homogenates in ethanol was an important step and effectively stabilized the β-sheet structure of the PrP^{Sc} isoform (Oesch et al., 1994), thereby increasing its protease resistance (Piesner et al., 1996).

Example 1.2. Western Blotting

Tissue specimens were homogenized as described in example 1.1., one part protease-digested, the other not (as described above), diluted to 10% and separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) on 12% gels (Sambrook et al., 1989). Gels were then electroblotted onto 0.45 µm nitrocellulose (NC) membranes, incubated with the respective monoclonal antibodies followed by a secondary anti-mouse IgG antibody coupled to peroxidase. Bound peroxidase activity was detected with a chemiluminescence kit (ECL, Amersham, USA).

Western blots developed with antibodies 6H4 or 34C9 (Figure 1a.) show the characteristic smear of bands for PrP^C and bovine PrP^{Sc} (33 to 27 kD) in undigested probes while digestion with proteinase K eliminates all of PrP^C, however, leaving a 27 kD band typical of N-terminally truncated PrP^{Sc}. The smear is due to different glycosylated forms of PrP.

The present antibodies were furthermore able to detect PrP in various tissue extracts from humans, cattle, pigs, sheep, mice and hamsters (Figures 1b and 2). Given that the epitopes of our antibodies are highly conserved (Oesch et al., 1991), we expect our antibodies to stain PrP from other species such as rat or deer as well.

Example 1.3. ELIFA (Enzyme Linked Immunofiltration Assay)

The ELIFA procedure to determine quantitatively the amounts of PrP^C and PrP^{Sc} in given tissue homogenates has been described for hamster brain homogenates (Oesch et al., 1994). Blotting directly on nitrocellulose has the advantage over the conventional ELISA procedure that the poor solubility of bovine PrP^{Sc} does not affect its immobilization on the solid phase. Blotting was performed with an ELIFA apparatus (Pierce), i.e. a peristaltic pump created a vacuum below the NC thereby sucking the contents of the wells above onto the NC in a controlled and highly reproducible way. Wells were then washed with PBS. The membrane was removed from the ELIFA apparatus, placed in a plastic tray and then incubated on a rocking table sequentially for the indicated times with the following reagents (inbetween steps, the filters were always washed 3x with PBS): 5% BSA/TBST (30min); avidin (25 µg/ml, 30min); biotin (2 µg/ml, 30min); monoclonal antibodies 6H4 or 34C9 in TBST (2 h RT or 10 h o/n); secondary, biotinylated anti-mouse IgG (Vectastain, USA, dilution 1:5000; 1 h RT); and streptavidin coupled to peroxidase (Boehringer, Germany, dilution 1:25000; 15-60 min RT).

In an alternative procedure, monoclonal antibodies 6H4 or 34C9 were biotinylated eliminating the step with the biotinylated secondary antibody. Still another procedure involved coupling of mABs 6H4 or 34C9 directly to peroxidase according to the manufacturer (Pierce, USA). Amplification of peroxidase activity was achieved by the ELAST-kit according to the manufacturer (DuPont, USA).

Subsequently, the NC was again placed in the ELIFA apparatus, a 96-well microtiterplate was placed underneath the membrane, such that each blotted spot corresponded to one well in that plate. Then the substrate TMB/peroxide (Kierkegaard & Perry) was applied into the wells of the ELIFA apparatus and sucked through the membrane into the wells of the microtiter plate. The reaction was stopped by the addition of 2M H₃PO₄. The extinction was measured at 450 nm with a reference at 620 nm in an ELISA reader.

The standard curve for the ELIFA (see Figure 3a) was obtained by serial dilutions of ultra-pure and defined amounts of recombinant bovine PrP (see below). For the ELIFA-procedure, lyophilized recombinant PrP was suspended in an antigen-dilution buffer (1M guanidinium thiocyanate and 0.01% human serum albumin in PBS). This buffer allows maximum binding of recombinant PrP to the nitrocellulose membrane. The standard curve is essential, since it allows to control both the quality and the reliability of the ELIFA-procedure. Furthermore, the standard curve allows to exactly quantify bovine PrP^C/PrP^{Sc} amounts in given tissue specimens (Oesch et al., 1994) (Figure 3a).

Example 1.4. Conventional ELISA (Enzyme Linked Immunosorbent Assay)

The antigen (present in a 10% homogenate as described in example 1.1.) was incubated for 2 h at RT in 96-well microtiterplates (Nunc, Denmark). Blocking was achieved with 5% BSA after antigen incubation. After washing, the plate was incubated with the biotinylated monoclonal antibody 6H4 for 2 h at RT. Washing with H₂O and PBS was performed before streptavidin-coupled peroxidase (Boehringer, Germany) was applied and peroxidase activity detected with the substrate according to the manufacturer (TMB/H₂O₂; Kierkegaard & Perry). The reaction was stopped by the addition of 2 M H₃PO₄. As for the ELIFA procedure, the plate is read by an ELISA reader at 450 nm with a reference at 620 nm. As an alternative procedure, peroxidase-coupled monoclonal antibody 6H4 was used instead of biotinylated antibody (see example 1.3.). Amplification of peroxidase activity was achieved by the ELAST-kit according to the manufacturer (DuPont, USA). Results of this immunological test are depicted in Figure 3c.

Example 1.5. Capture-ELISA (Enzyme Linked Immuno Sorbent Assay)

For the capture-ELISA, advantage can be taken of the multimeric nature of disease-specific PrP^{Sc}. Using the same monoclonal antibody for coating the wells and detection of native PrP (e.g. mAB 6H4) will detect only PrP that exists in multimeric form or aggregated states, since monomeric PrP will have blocked its single binding site for the detection mAB by the coating mAB. Multimeric PrP^{Sc} will be detected because apart from the one mAB binding site that couples the multimeric PrP to the microtiter plate, other binding sites are still present for the detection antibodies (see Figure 4). This particular procedure of a capture-ELISA for PrP^{Sc} detection can only be performed with the present monoclonal antibodies binding to native PrP^{Sc}, since upon denaturation the multimeric PrP^{Sc} complexes dissociate into multiple monomeric, denatured PrP molecules.

For the capture ELISA, monoclonal antibodies according to the invention were either covalently linked or coated to microtiterplates (Nunc, Denmark). Subsequently, the wells were blocked with 5% BSA for 30 min at RT and the procedure according to example 1.4. followed.

Example 2. Experimental details for the production of monoclonal antibodies specific for the native and denatured prion protein

Example 2.1. Preparation of the immunogen

The following primers were chosen to amplify PrP DNA from bovine genomic DNA:

1. N-terminal sense primer (SEQ ID NO: 3):
5'-GGGAATTCCATATGAAGAAGCGACCAAAACCTG-3' and
2. C-terminal antisense primer (SEQ ID NO: 4):
5'-CGGGATCCTATTAACCTGCCCCTCGTTGGTA-3'.

These primers were designed to introduce an Nde I restriction site at the 5' end and a BamH I restriction site at the 3' end in the PCR-amplified bovine PrP-DNA. 10 cycles of 1 min 94°C, 2 min 42°C and 2 min 72°C, followed by 4x5 cycles of 1 min 94°C, 1 min 63°C and 72°C with increasing durations of 1, 2, 3 and 4 min were performed in a Crocodile III thermocycler (Appliedgene, USA).

The PCR product was digested with the restriction enzymes Nde I and BamH I (Boehringer, Germany). The appropriate DNA fragment of 650 bp was purified on a 1% agarose gel and ligated into the pET11a vector (Novagen) previously digested with Nde I and BamHI. Ligated products were transfected into *E. coli* strain DH5 α . The appropriate clone containing the PrP open reading frame in the pET11a vector was selected and subsequently termed pbPrP3 (Figure 5). Sequencing of the PrP sequence in pbPrP3 confirmed that the sequence of the bovine PrP gene in the pET11a vector corresponds to the previously published sequence (Goldmann et al., 1991; SEQ ID NO: 1). Plasmid pbPrP3 was transfected into *E. coli* strain BL21(DE3) (Novagen), that is capable of translating the plasmid into a protein. For production of bovine PrP, cells were stimulated with 1 mM IPTG according to standard techniques (Sambrook et al., 1989). Recombinant bovine PrP was purified from inclusion bodies. For example, 1 liter of Luria broth medium (Gibco, USA) containing 100 μ g/ml ampicillin was incubated with an overnight culture (4 ml) of pbPrP3 transfected BL21(DE3) cells. The culture was then grown at 37°C and 250 rpm to an OD₆₀₀ of 0.8. IPTG was added to a final concentration of 1 mM and the incubation was continued at 30°C and 250 rpm for 3h until the OD₆₀₀ was 1.0. The culture was then centrifuged at 1000 x g for 5 min at RT. The pellet containing the bacteria was further processed for isolation of PrP from inclusion bodies as follows: the bacterial pellet from a 1 liter culture was resuspended in 100 ml of 2 mM EDTA, 50 mM Tris-HCl pH 7.5 and lysed by the addition of lysozyme (final concentration 100 mg/ml) and Triton-X-100 (final conc. 1%) for 15 min at 37°C. Then, MgCl₂ (final conc. 15 mM) and DNase I (final conc. 10 μ g/ml) were added. The suspension was shaken at room temperature until the DNA was digested and the solution was clear (30 min). The solution was then centrifuged at 10.000 x g for 30 min at 4°C. The supernatant containing all the soluble proteins was discarded and the pellet, containing the inclusion bodies, was homogenized and resuspended in 1/10th of the original culture volume containing 8M deionized urea, 10 mM MOPS pH 7.5. This suspension was then shaken at room temperature overnight and then centrifuged at 10.000 x g for 30 min at 4°C. The supernatant containing solubilized material from inclusion bodies was then further processed.

A carboxymethyl (CM) sepharose column (Pharmacia) was equilibrated first with the elution buffer containing 8M deionized urea, 500 mM NaCl, 10mM MOPS pH 7.5, then with the washing buffer containing 8M deionized urea, 10mM MOPS pH 7. A CM sepharose column (50 ml bed volume) was loaded with 100 ml of the solution containing the solubilized proteins from inclusion bodies. The column was washed twice with 25 ml 50 mM NaCl, 8M urea, 10 mM MOPS and once with 100 mM NaCl, 8M urea, 10 mM MOPS. Bovine recombinant PrP was eluted with 500 mM NaCl, 8M urea, 10 mM MOPS. SDS-PAGE and silver staining showed that at this step only one protein of about 24 kD was present in the eluent, corresponding to the calculated molecular weight of 23,6 kD (Figure 6a). This fraction was then further processed.

Proteins eluted from the CM sepharose were subsequently either oxidized with 10 μ M Cu₂SO₄ or reduced with 2% β -mercaptoethanol for several hours before they were loaded on a C₄-reverse phase HPLC column. The HPLC column was perfused with a 0-85% gradient of acetonitrile in 0.1% trifluoroacetic acid (TFA). The oxidized or reduced bovine recombinant PrP eluted about 40 or 45% acetonitrile, respectively. The eluted fractions were lyophilized (Sambrook et al., 1989) and redissolved in distilled water. Electrospray mass spectroscopy revealed single peaks of 23676.8 and 23686.1 Dalton for oxidized and reduced recombinant bovine PrP, respectively, indicating a correct and uniform translation of the bovine PrP open reading frame in pbPrP3.

Example 2.2.: Immunization of animals and hybridoma production

Oxidized or reduced bovine recombinant PrP or a mixture of both amounting to a total of 100 μ g in a single dose (dissolved in PBS) were used to immunize PrP^{0/0} mice, i.e. mice without a functional PrP gene (Bueler et al., 1992) that

were kindly provided by Prof. C. Weissmann, University of Zurich. The reduced form of the recombinant PrP was particularly interesting since it has been reported to contain more β -sheet secondary structures than the oxidized form in a recombinant Syrian hamster PrP fragment (Mehlhorn et al., 1996), hence mimicking structural features of PrP^{Sc}, however, the reduced recombinant isoforms have been reported to be neither protease-resistant nor infectious (Mehlhorn et al., 1996).

Mice received three subcutaneous injections (day 0 with Freund's complete adjuvans, days 21 and 42 with Freund's incomplete adjuvans) of the antigens in a constant 100 μ g amount and in a volume of 100 μ l. On day 49 mice were boosted with the antigen intraperitoneally and the next day intravenously with adjuvant Pertussi Berna (Berna, Switzerland; extract of Bordetella pertussis bacteria). On day 50 mice were anesthetized and decapitated. The spleen from immunized mice was removed, and splenocytes were recovered. Mouse myeloma cells (cell line P3X63Ag8U.1, ATCC CRL 1597; Scharff, 1978) were mixed to the splenocytes at a ratio of 1:5 and fused by the addition of 50% PEG (polyethylenglycol) for 8 min at RT according to standard techniques (Kennett, 1980). Cells were then washed and grown overnight. The next day, cells were suspended in selective medium (HAT) and plated in 96-well microtiterplates. The selective medium contains aminopterin that is toxic for those cells that have not been fused to splenocytes and thus eliminates uncontrolled cell growth of irrelevant cells (Kennett, 1980).

Example 2.3.: Screening hybridomas for specific antibodies

Most important was an efficient screening method for antibody-producing hybridoma cell lines that would allow to detect monoclonal antibodies against native and denatured epitopes of both PrP isoforms, as well as conformation-specific epitopes of bovine PrP^{Sc}. The screening for hybridoma cells producing antibodies against PrP was done by an ELISA, Western blotting and a conformation-sensitive ELIFA.

ELISA using recombinant bovine PrP

96-well microtiter plates were coated with recombinant bovine PrP (0.25 μ g/well) for 4 h at RT and then blocked with 5% BSA/H₂O for 1h at RT. After washing with H₂O and PBS, culture medium from wells containing hybridoma colonies was transferred to the microtiter plates (50 μ l per well) and incubated overnight at 4°C. After washing with H₂O and PBS, bound antibodies were detected with a peroxidase-labeled anti-mouse IgG antibody (Cappel, Switzerland) followed by colorimetric detection with TMB/H₂O₂ (Kierkegaard & Perry, USA) as described in example 1.4.

Qualitative, conformation-sensitive ELIFA

1% brain homogenates of normal and BSE-infected cattle were either left undigested or protease-digested for the BSE brain homogenate and blotted onto a nitrocellulose membrane as described by for the ELIFA procedure (see above) (Oesch et al., 1994). After blotting, the membrane was blocked with 5% low-fat milk in TBST, and incubated with the antibody-containing culture medium. Subsequently, the NC was incubated with a secondary, peroxidase-coupled anti-mouse IgG antibody and developed with a chemiluminescence kit (ECL; Amersham). This technique allowed for detection of hybridoma cell lines that produce antibodies against native PrP^C and bovine PrP^{Sc} or of conformation-sensitive antibodies that distinguish between PrP^C and bovine PrP^{Sc} (as described for mAB 15B3 in Figure 6b).

Western Blotting

Hybridoma cell lines were further selected on the capability of the produced antibodies to recognize PrP of brain homogenates and recombinant bovine PrP on Western blots. Brain homogenates of various tissues and various species were blotted as described in example 1.2..

It was shown that the preferred mAB 6H4 recognizes PrP in the brain homogenates of cattle, mice, hamsters, pig, sheep and humans (Figure 2).

The preferred mAB 34C9 recognizes PrP in the brain homogenates of cattle, mice, pig, and humans (Figure 2).

It was further shown that both preferred monoclonal antibodies 6H4 and 34C9 recognize bovine PrP in various tissues such as medulla, spinal cord, thalamus, cortex and white blood cells (Figures 1a, and b).

Mapping of epitopes

A peptide library consisting of 104 peptides numbered 1 to 104, purchased from Jerini Biotools (Berlin, Germany) was used to map the epitopes that are recognized by the antibodies. The peptides are covalently linked to a cellulose membrane, have each a length of 13 amino acids and together cover the entire length of the bovine prion protein (total of 104). Each peptide overlaps by 11 amino acids with the next peptide. Binding of antibodies to those peptides can be

visualized by the ECL system as described for Western blotting in Example 1.2.

The monoclonal antibodies of the present invention bound to peptides comprised in the region of helix 1 in the three-dimensional model of the mouse recombinant C-terminal prion protein fragment described by Riek et al. (1996). It is hereby assumed that this mouse recombinant C-terminal prion protein fragment reflects the structure of native PrP^C, has the same structure as full length PrP and that the structure will be similar in different species. Based on these assumptions the following statements are mAB 6H4 binds to the three library peptides Nos. 64 to 66, comprising amino acids 155-163 of the bovine PrP sequence SEQ ID NO: 1 (Figure 7b). This sequence corresponds exactly to the full-length helix, a structure that is highly conserved between species (Oesch et al., 1991).

mAB 34C9 binds to the 5 library peptides Nos. 59 to 63 comprising amino acid 149-153 of the bovine PrP sequence SEQ ID NO: 1 (Figure 7a) which corresponds to a sequence just N-terminal of helix 1 (Riek et al., 1996).

As predicted by this epitope mapping, the monoclonal antibodies differentially bind PrP from different species (Figure 2).

Characterization of PrP^{Sc} conformation-specific monoclonal antibody 15B3

mAB15B3 binds to the 7 library peptides Nos. 73 to 79 comprising amino acids 140-152 of the bovine PrP sequence SEQ ID NO: 1 (Figure 7c), and additional "patches" situated on library peptides Nos. 33-34, 52 and 69.

Monoclonal antibody 15B3 recognizes native bovine PrP^{Sc} better than native bovine PrP^C (Figure 6b). In this experiment, 10% bovine brain homogenates of normal undigested and BSE-diseased protease-digested cattle were made as described in Example 1.1. Subsequently, the samples were diluted to a 0.5% homogenate with either PBS, 4M or 8M deionized urea/PBS buffer and incubated at 37°C for 1h. The samples were then blotted onto a nitrocellulose membrane with the qualitative, conformation-sensitive ELIFA protocol as described in example 3 above. In Figure 6b, it can be seen that upon denaturation with urea, the specific discrimination between PrP^C and PrP^{Sc} is not further present. This suggests that mAB 15B3 recognizes an epitope that is hidden in PrP^C as compared to PrP^{Sc} but that becomes accessible upon denaturation. By Western blotting, PrP from bovine brain homogenates cannot be detected (Figure 6a). However, recombinant bovine PrP is recognized, giving evidence that mAB 15B3 in fact detects PrP. Apparently mAB cannot detect PrP on Western blotting, even if it is assumed that proteins denature in sample buffer containing SDS before they are loaded on the gel (Example 1.2.; Sambrook et al. 1989).

These two findings, i.e. detection upon urea denaturation on the ELIFA and missing detection on denaturation after Western blotting, point to the fact that mAB 15B3 binds to a conformation-sensitive epitope that is coupled to β -sheet structure since it is this structure that is disrupted by SDS addition during the Western blotting procedure. As can be seen in the binding experiments with the peptide library, mAB 15B3 binds to several distant peptides as would be expected for a conformation-sensitive mAB. In addition, the long stretch of peptides from 73 to 79 on the peptide library corresponds to the amino acids 140 to 152 of PrP (SEQ ID NO: 1) that partially comprises the β -sheet containing strand 2 in the three-dimensional PrP model of Riek et al. (1996). Moreover, the few distant peptides that stain positive in the peptide library (Figure 7) are all near this strand 2 in the Riek et al. model. Thus, mAB 15B3 binds to a β -sheet comprising epitope that is present in native specific PrP^{Sc}, but not in native normal PrP^C.

Example 3: Reduction of infectivity of prions by monoclonal antibodies

Brain homogenates from BSE-infected cattle are obtained as described in Example 1.1. The exact amount of present bovine PrP^{Sc} are measured with the help of the ELIFA technique or the ELISA technique as described in examples 1.3 to 1.5, respectively. Serial dilutions of this infected brain homogenate are aliquoted. To these serial dilutions are added the preferred mABs 6H4, 34C9 or 15B3, or a mixture thereof, in molar amounts exceeding the molar amounts of measured PrP^{Sc}. The mix is incubated for 4h at RT and then 100 μ l are injected intracerebrally into the animal. Transgenic mice overexpressing mouse PrP (tg35; Fischer et al., 1996) are used as an animal model for measuring the infectivity of bovine PrP^{Sc}.

List of buffers and solutions

HT-medium 450 ml Iscove's modified Dulbecco's medium (GIBCO)
30 ml sterile human serum
5 ml glutamine (200 mM)
5 ml hypoxanthine (10 mM)/thymidine (1.5 mM)
5 ml penicillin (10000 IU/ml)/streptomycin (10000mg/ml)
250 ml sterile b-mercaptoethanol
HAT-medium HT-medium + 2mM aminopterin
TBS 20 mM Tris pH 7.5

150 mM NaCl
 TBST 20 mM Tris pH 7.5
 150 mM NaCl
 0.05% Tween 20

Deposit of microorganisms

The hybridoma cell lines were deposited under the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, as follows:

1. Hybridoma cell line producing mAB 34C9: DSM ACC2295, deposited February 06, 1997
2. Hybridoma cell line producing mAB 6H4: DSM ACC2296, deposited February 06, 1997
3. Hybridoma cell line producing mAB 15H3: DSM ACC2298, deposited February 13, 1997

References

- Alper, T., Haig, D.A., and Clarke, M.C. (1978). The scrapie agent: evidence against its dependence for replication on intrinsic nucleic acid. *J. Gen. Virol.* 41, 503-516.
- Anderson, R.M., Donnelly, C.A., Ferguson, N.M., Woolhouse, M.E.J., Watt, C.J., Udy, H.J., MaWinney, S., Dunstan, S.P., Southwood, T.R.E., Wilesmith, J.W., Ryan, J.B.M., Hoinville, L.J., Hillerton, J.E., Austin, A.R., and Wells, G.A.H. (1996). Transmission dynamics and epidemiology of BSE in british cattle. *Nature* 382, 779-788.
- Barry, R.A., Kent, S.B., McKinley, M.P., Meyer, R.K., DeArmond, S.J., Hood, L.E., and Prusiner, S.B. (1986). Scrapie and cellular prion proteins share polypeptide epitopes. *J. Infect. Dis.* 153, 848-854.
- Barry, R.A. and Prusiner, S.B. (1986). Monoclonal antibodies to the cellular and scrapie prion proteins. *J. Infect. Dis.* 154, 518-521.
- Basler, K., Oesch, B., Scott, M., Westaway, D., Walchli, M., Groth, D.F., Mc Kinley, M.P., Prusiner, S.B., and Weissmann, C. (1986). Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. *Cell* 46, 417-428.
- Bessen, R.A., Kocisko, D.A., Raymond, G.J., Nandan, S., Lansbury, P.T., and Caughey, B. (1995). Non-genetic propagation of strain-specific properties of scrapie prion protein (see comments). *Nature* 375, 698-700.
- Bolton, D.C., McKinley, M.P., and Prusiner, S.B. (1982). Identification of a protein that purifies with the scrapie prion. *Science* 218, 1309-1311.
- Bruce, M., Chree, A., McConnell, I., Foster, J., Pearson, G., and Fraser, H. (1994). Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* 343, 405-411.
- Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H.P., DeArmond, S.J., Prusiner, S.B., Aguet, M., and Weissmann, C. (1992). Normal development and behaviour of mice lacking the neuronal cell- surface PrP protein (see comments). *Nature* 356, 577-582.
- Bueler, H., Aguzzi, A., Sailer, A., Greiner, R.A., Autenried, P., Aguet, M., and Weissmann, C. (1993). Mice devoid of PrP are resistant to scrapie. *Cell* 73, 1339-1347.
- Cohen, F.E., Pan, K.M., Huang, Z., Baldwin, M., Fletterick, R.J., and Prusiner, S.B. (1994). Structural clues to prion replication. *Science* 264, 530-531.
- Collinge, J., Whittington, M.A., Sidle, K.C., Smith, C.J., Palmer, M.S., Clarke, A.R., and Jefferys, J.G. (1994). Prion protein is necessary for normal synaptic function. *Nature* 370, 295-297.
- Collinge, J., Sidle, K.C.L., Meads, J., Ironside, J., and Hill, A.F. (1996). Molecular analysis of prion strain variation and the etiology of a "new variant" CJD. *Nature* 383, 683-690.
- Diener, T.O., McKinley, M.P., and Prusiner, S.B. (1982). Viroids and prions. *Proc. Natl. Acad. Sci. U. S. A.* 79, 5220-5224.
- Friden, P.M. (1994). Receptor-mediated transport of therapeutics across the blood-brain barrier. *Neurosurgery* 35, 294-298. (Abstract)
- Garfin, D.E., Stites, D.P., Perlman, J.D., Cochran, S.P., and Prusiner, S.B. (1978). Mitogen stimulation of splenocytes from mice infected with scrapie agent. *J. Infect. Dis.* 138, 396-400.
- Griffith, J.S. (1967). Self-replication and scrapie. *Nature* 215, 1043-1044.
- Hecker, R., Taraboulos, A., Scott, M., Pan, K.M., Yang, S.L., Torchia, M., Jendroska, K., DeArmond, S.J., and Prusiner, S.B. (1992). Replication of distinct scrapie prion isolates is region specific in brains of transgenic mice and hamsters. *Genes Dev.* 6, 1213-1228.
- Hope, J., Reekie, L.J., Hunter, N., Multhaup, G., Beyreuther, K., White, H., Scott, A.C., Stack, M.J., Dawson, M., and Wells, G.A. (1988). Fibrils from brains of cows with new cattle disease contain scrapie- associated protein.

Nature 336, 390-392.

Jendroska, K., Heinzl, F.P., Torchia, M., Stowring, L., Kretzschmar, H.A., Kon, A., Stern, A., Prusiner, S.B., and DeArmond, S.J. (1991). Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity. *Neurology* 41, 1482-1490.

Kascsak, R.J., Rubenstein, R., Merz, P.A., Tonna DeMasi, M., Fersko, R., Carp, R.I., Wisniewski, H.M., and Diringer, H. (1987). Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. *J. Virol.* 61, 3688-3693.

Kasper, K.C., Stites, D.P., Bowman, K.A., Panitch, H., and Prusiner, S.B. (1982). Immunological studies of scrapie infection. *J. Neuroimmunol.* 3, 187-201.

Kocisko, D.A., Come, J.H., Priola, S.A., Chesebro, B., Haymond, G.J., Lansbury, P.T., and Caughey, B. (1994). Cell-free formation of protease-resistant prion protein. *Nature* 370, 471-474.

Krasemann, S., Groschup, M., Harmeyer, S., Hunsmann, G., and Bodemer, W. (1996). Generation of monoclonal antibodies against human prion proteins in PrP^{0/0}-mice. *Molecular Medicine* 2, 725-734.

Oesch, B., Westaway, D., Walchli, M., McKinley, M.P., Kent, S.B., Aebersold, R., Barry, R.A., Tempst, P., Teplow, D.B., and Hood, L.E. (1985). A cellular gene encodes scrapie PrP 27-30 protein. *Cell* 40, 735-746.

Oesch, B., Jensen, M., Nilsson, P., and Fogh, J. (1994). Properties of the scrapie prion protein: quantitative analysis of protease resistance. *Biochemistry* 33, 5926-5931.

Pan, K.M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R.J., Cohen, F.E., and Prusiner, S.B. (1993). Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc. Natl. Acad. Sci. U. S. A.* 90, 10962-10966.

Prusiner, S.B. (1982). Novel proteinaceous infectious particles cause scrapie. *Science* 216, 136-144.

Prusiner, S.B. (1991). Molecular biology of prion diseases. *Science* 252, 1515-1522.

Prusiner, S.B., Groth, D., Serban, A., Koehler, R., Foster, D., Torchia, M., Burton, D., Yang, S.L., and DeArmond, S.J. (1993). Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. *Proc. Natl. Acad. Sci. U. S. A.* 90, 10608-10612.

Riesner, D., Kellings, K., Wiese, U., Wulfert, M., Mirenda, C., and Prusiner, S.B. (1993). Prions and nucleic acids: search for "residual" nucleic acids and screening for mutations in the PrP-gene. *Dev. Biol. Stand.* 80, 173-181.

Scharff, M.D. (1978). *Current Topics in Microbiology and Immunology* 81, 1-7.

Serban, D., Taraboulos, A., DeArmond, S.J., and Prusiner, S.B. (1990). Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins. *Neurology* 40, 110-117.

Stahl, N., Borchelt, D.R., Hsiao, K., and Prusiner, S.B. (1987). Scrapie prion protein contains a phosphatidylinositol glycolipid. *Cell* 51, 229-240.

Stahl, N., Baldwin, M.A., Teplow, D.B., Hood, L., Gibson, B.W., Burlingame, A.L., and Prusiner, S.B. (1993). Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. *Biochemistry* 32, 1991-2002.

Takahashi, K., Shinagawa, M., Doi, S., Sasaki, S., Goto, H., and Sato, G. (1986). Purification of scrapie agent from infected animal brains and raising of antibodies to the purified fraction. *Microbiol. Immunol.* 30, 123-131.

Tobler, I., Gaus, S.E., Deboer, T., Achermann, P., Fischer, M., Rulicke, T., Moser, M., Oesch, B., McBride, P.A., and Manson, J.C. (1996). Altered circadian activity rhythms and sleep in mice devoid of prion protein. *Nature* 380, 639-642.

Wells, G.A. and Wilesmith, J.W. (1995). The neuropathology and epidemiology of bovine spongiform encephalopathy. *Brain Pathol.* 5, 91-103.

Will, R.G., Ironside, J.W., Zeidler, M., Cousens, S.N., Estibeiro, K., Alperovitch, A., Poser, S., Pocchiari, M., Hofman, A., and Smith, P.G. (1996). A new variant of Creutzfeldt-Jakob disease in the UK (see comments). *Lancet* 347, 921-925.

Williams, A.E., Lawson, L.J., Perry, V.H., and Fraser, H. (1994). Characterization of the microglial response in murine scrapie. *Neuropathol. Appl. Neurobiol.* 20, 47-55.

Williams, A.E., Ryder, S., and Blakemore, W.F. (1995). Monocyte recruitment into the scrapie-affected brain. *Acta Neuropathol.* 90, 164-169.

Williamson, R.A., Peretz, D., Smorodinsky, N., Bastidas, R., Serban, H., Mehlhorn, I., DeArmond, S.J., Prusiner, S.B., Burton, D.R., Mouse antibody libraries, Phage display, Gene ablation, Scrapie, Prion, and disease. (1996). Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. *Proceedings of the National Academy of Sciences of the United States of America* 93, 7279-7282.

5

10

15

20

25

30

35

40

45

50

55

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Bos taurus

(D) DEVELOPMENTAL STAGE: Adult

(vii) IMMEDIATE SOURCE:

(B) CLONE: pbPrP3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATGAAGAAGC	GACCAAAACC	TGGAGGAGGA	TGGAACACTG	GGGGGAGCCG	ATACCCAGGA	60
CAGGGCAGTC	CTGGAGGCAA	CCGTTATCCA	CCTCAGGGAG	GGGGTGGCTG	GGGTCAGCCC	120
CATGGAGGTG	GCTGGGGCCA	GCCTCATGGA	GGTGGCTGGG	GCCAGCCTCA	TGGAGGTGGC	180
TGGGGTCAGC	CCCATGGTGG	TGGCTGGGGA	CAGCCACATG	GTGGTGGAGG	CTGGGGTCAA	240
GGTGGTACCC	ACGGTCAATG	GAACAAACCC	AGTAAGCCAA	AAACCAACAT	GAAGCATGTG	300
GCAGGAGCTG	CTGCAGCTGG	AGCAGTGGTA	GGGGGCCTTG	GTGGCTACAT	GCTGGGAAGT	360
GCCATGAGCA	GGCCTCTTAT	ACATTTTGGC	AGTGACTATG	AGGACCGTTA	CTATCGTGAA	420
AACATGCACC	GTTACCCCAA	CCAAGTGTA	TACAGGCCAG	TGGATCAGTA	TAGTAACCAG	480
AACAACCTTG	TGCATGACTG	TGTCAACATC	ACAGTCAAGG	AACACACAGT	CACCACCACC	540
ACCAAGGGGG	AGAACTTCAC	CGAAACTGAC	ATCAAGATGA	TGGAGCGAGT	GGTGGAGCAA	600
ATGTGCATTA	CCCAGTACCA	GAGAGAATCC	CAGGCTTATT	ACCAACGAGG	GGCAAGTTAA	660

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 219 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Bos taurus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Lys Lys Arg Pro Lys Pro Gly Gly Gly Trp Asn Thr Gly Gly Ser
 1 5 10 15

Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg Tyr Pro Pro Gln
 20 25 30

Gly Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro
 35 40 45

His Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro
 50 55 60

His Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Gly Trp Gly Gln
 65 70 75 80

Gly Gly Thr His Gly Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn
 85 90 95

Met Lys His Val Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly
 100 105 110

Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile His
 115 120 125

EP 0 861 900 A1

Phe Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met His Arg
130 135 140

Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln
145 150 155 160

Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Val Lys Glu His Thr
165 170 175

Val Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys
180 185 190

Met Met Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln Tyr Gln Arg
195 200 205

Glu Ser Gln Ala Tyr Tyr Gln Arg Gly Ala Ser
210 215

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GGGAATTCCA TATGAAGAAG CGACCAAAAC CTG

33

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligonucleotide"

10

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

20

CGGGATCCTA TTAAGTTGCC CCTCGTTGGT A

31

25

Claims

1. A monoclonal antibody or a fragment thereof capable of specifically binding to native and denatured normal (PrP^C) and disease-specific prion protein (PrP^{Sc}) in an antigen-antibody complex.
2. A monoclonal antibody according to claim 1 which is only capable of binding to native disease-specific prion protein and not to native normal prion protein.
3. A monoclonal antibody according to claim 1 wherein the prion protein is soluble.
4. A monoclonal antibody according to claim 1 wherein the prion protein is insoluble.
5. A monoclonal antibody according to claim 1 wherein the prion protein is a recombinant prion protein.
6. A monoclonal antibody according to claim 1 wherein the prion protein is reduced.
7. A monoclonal antibody according to claim 1 wherein the prion protein is oxidized.
8. A monoclonal antibody according to claim 1 which is named 6H4.
9. A monoclonal antibody according to claim 1 which is named 34C9.
10. A monoclonal antibody according to claim 2 which is named 15B3.
11. A monoclonal antibody according to claim 1 or 2 which comprises an epitope binding fragment of anyone of the monoclonal antibodies 6H4, 34C9 or 15B3.
12. A monoclonal antibody according to claim 1 or 2 coupled to other molecules especially fragments of other antibodies, enzymes or organic chemical compounds.
13. An antibody raised against the binding region (idiotype) of the antibodies according to claim 1 or 2.
14. A hybridoma cell line capable of producing a monoclonal antibody according to anyone of claims 1-13.

15. A hybridoma cell line according to claim 14 deposited under DSM ACC2295 capable of producing the monoclonal antibody 6H4.
- 5 16. A hybridoma cell line according to claim 14 deposited under DSM ACC2296 capable of producing the monoclonal antibody 34C9.
17. A hybridoma cell line according to claim 14 deposited under DSM ACC2298 capable of producing the monoclonal antibody 15B3.
- 10 18. A recombinant expression vector for the expression of the bovine prion protein.
19. A recombinant expression vector according to claim 18 which is pbPrP3.
20. The purified recombinant bovine prion protein in reduced or oxidized form or in form of a mixture thereof.
- 15 21. A method for the production of an antibody according to claim 1, comprising culturing a hybridoma cell line according to claim 14 and isolating the monoclonal antibody from the supernatant.
- 20 22. A method for the production of a hybridoma cell line according to claim 14, comprising administering to PrP^{0/0} mice (knockout mice without a functional PrP gene) an immunizing amount of a prion protein according to claim 20, removing the spleen from the immunized mice, recovering splenocytes therefrom, fusing the latter with a myeloma cell line, growing the fused cells in a selection medium, screening the antibodies in the supernatants of hybridoma cells for binding to native disease-specific and recombinant PrP and isolating the hybridoma cells producing monoclonal antibodies according to claim 1.
- 25 23. A method for the production of an expression vector according to claim 18, comprising inserting a DNA coding for the bovine PrP in the correct reading frame into an expression vector.
- 30 24. A method for the production of a purified bovine recombinant PrP comprising culturing a microorganism or eukaryotic cell line with an expression vector according to claim 18 in an appropriate culture medium and isolating and purifying the protein.
- 35 25. A test kit for the diagnosis of prion diseases comprising one or more monoclonal antibodies according to claim 1, purified recombinant bovine PrP protein according to claim 20, nitrocellulose sheets, microtiter plates coated or covalently linked with monoclonal antibodies according to claim 1, an antibody that is coupled with an enzyme and its substrate for a detection reaction, proteinase K, blocking buffer, homogenisation buffer and a detailed description of how to perform the test.
- 40 26. A test kit according to claim 25 comprising a nitrocellulose membrane in the dipstick format coated with an antibody according to claim 1 or 2, a dilution buffer, a solution containing an antibody according to claim 1 or 2, coupled to colloids evoking a colouring reaction when present in an antigen-antibody complex, and a detailed description of how to perform the test.
- 45 27. An immunological detection procedure for the detection of disease-specific PrP in biological material of an animal or human comprising treatment of a probe of said material with proteinase K and then with the monoclonal antibody according to claim 1 or 2, detecting the prion protein-antibody complex and analysing the results.
- 50 28. An immunological detection procedure according to claim 27 comprising treatment of a probe of said material with the monoclonal antibody according to claim 2, without prior treatment with proteinase K, detecting the prion protein-antibody complex and analysing the results.
- 55 29. A pharmaceutical preparation for the therapy and prevention of prion diseases comprising a monoclonal antibody or fragments thereof according to claim 1 or 2 and a pharmaceutical carrier.
30. A method for the therapy or prevention of prion diseases comprising administering to a patient suffering from such disease or being likely to becoming a victim of this disease a therapeutical or preventive amount of a monoclonal antibody according to claim 1 or 2.

31. A method for clearing biological material from prions comprising treating said material with a monoclonal antibody according to claim 1 or 2.

5

10

15

20

25

30

35

40

45

50

55

Figure 1





Figure 2



Figure 3


Standard-curve of ELIFA

a.



ELIFA for the detection of bovine PrP^{Sc}

b.



ELISA for the detection of bovine PrP^{Sc}

c.




Figure 4

Capture-ELISA and multimeric PrP^{Sc}




Figure 5




Figure 6








Figure 7



peptides 59-63, comprising amino acids
149-153 of rbPrP



peptides 64-66, comprising amino acids
155-163 of rbPrP



longest peptide stretch from 73 to 79,
comprising amino acids
175-187 of rbPrP



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 97 10 2837 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X,0	SOCIETY FOR NEUROSCIENCE, ABSTRACTS, vol. 22, no. 1-3, 16 - 21 November 1996, page 2159 XP002036864 C. KORTH ET AL.: "Characterization of native and recombinant prion protein isoforms by differential exposure of antibody epitopes." * abstract 844.3 *	1-7,27, 28	C12N15/70 C07K16/18 C12N5/20 C07K14/47 C12N15/06 C12N1/21 C12N5/10 G01N33/577 G01N33/68 A61K39/395
X	DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, vol. 80, 1993, BASEL, pages 141-151, XP002036865 R. KASCSAK ET AL.: "The role of antibodies to PrP in the diagnosis of transmissible spongiform encephalopathies." * the whole document *	1-7,27, 28	
X	WO 93 23432 A (NEW YORK UNIVERSITY ET AL.) 25 November 1993 * the whole document *	1,3,27, 28	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C07K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		5 August 1997	Nooi, F
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>		<p>I : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>	

EP0 FORM 1503 (03.92) (P04007)

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 97 10 2837

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	<p>LAIT, vol. 76, no. 6, November 1996, PARIS, pages 571-578, XP002036866 A. PARAF: "Scrapie and bovine spongiform encephalopathy: immunological properties and diagnosis for food products." * the whole document *</p> <p>---</p>	1-31	
A	<p>JOURNAL OF INFECTIOUS DISEASES, vol. 167, March 1993, pages 602-613, XP002036867 S. PRUSINER ET AL.: "Immunologic and molecular biologic studies of prion proteins in bovine spongiform encephalopathy." * the whole document *</p> <p>---</p>	1-31	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
A	<p>JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT, vol. 18 part D, 1994, page 198 XP002036868 M. CANN ET AL.: "Antibody fragments to PrP generated using phage display technology." * abstract T304 *</p> <p>---</p>	1-31	
A	<p>NATURE, vol. 381, no. 6583, 13 June 1996, LONDON, page 563 XP000579899 B. SCHREUDER ET AL.: "Preclinical test for prion diseases." * the whole document *</p> <p>---</p>	1-31	
	-/--		

Application Number
EP 97 10 2837

EPO FORM ISOJ 03.02 (POMC10)



European Patent Office

EP 97 10 2837 -C-

INCOMPLETE SEARCH

The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.

Claims searched completely:
 Claims searched incompletely:
 Claims not searched:

Reason for the limitation of the search:

Remark: Although claim 30
 is directed to a method of
 treatment of the human/animal
 body (Art. 52(4) EPC) the search
 has been carried out and based on
 the alleged effects of the
 compound/composition